Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-Week data from the European cohort of the PREDICTIVE study

Current Medical Research and Opinion

Volumn 24, Issue 2, 2008, Pages 369-376

  Dornhorst, Anne ^a   Lüddeke, Hans Joachim ^b   Honka, Marek ^c   Ackermann, Ralf W ^d   Meriläinen, Markus ^d   Gallwitz, Baptist ^e   Sreenan, Seamus ^f  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Praxis Lüddeke Trauner   (Germany)

^c Fakultni Nemocnice S Poliklinikou Ostrava   (Czech Republic)

^d NOVO NORDISK A S   (Denmark)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f Royal College of Surgeons in Ireland   (Ireland)

Author keywords

Glycaemic control; Hypoglycaemia; Insulin detemir; Observational; Type 1 diabetes; Weight neutrality

Indexed keywords

GLUCOSE; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DRUG TOXICITY; EUROPE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 39749086919     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X260835     Document Type: Article

References (35)

1. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006;29 (Suppl 1):S4-42
2. American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management - 2002 update. Endocr Pract 2002;8(Suppl 1):43-84
3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
4. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26:1902-12
5. Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J Diabetes Comp 2004;18:60-8
6. Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes 1993;42:1700-7
7. Davies M. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes Relat Metab Disord 2004;28(Suppl 2):S14-22
8. New J, Hollis S, Campbell F, et al. Measuring clinical performance and outcomes from diabetes information systems: an observational study. Diabetologia 2000;43:836-43
9. Duckworth WC. Hyperglycemia and cardiovascular disease. Curr Atheroscler Rep 2001;3:383-91
10. Writing team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-9
11. Writing team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-67
12. Nathan DM, Cleary PA, Backhand JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
13. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-9
14. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999;55:199-203
15. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999;22:1501-6
16. Heinemann L, Linkeschova R, Rave K, Hompesch B, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9
17. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005;28:1107-12
18. Milicevic Z, Profozic V, Wyatt J, et al. Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in type 2 diabetes. Diabet Med 2001;18:562-6
19. Plank J, Wutte A, Brunner G, et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002;25:2053-7
20. Osterberg O, Erichsen L, Ingwersen SH, et al. Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. J Pharmacokinet Pharmacodynam 2003;30:221-35
21. Becker RH, Frick AD, Burger F, et al. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005;113:435-43
22. Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-83
23. Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-9
24. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care. 2004;27:1081-7
25. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005;22:850-7
26. Heise T, Nosek L, Ronn B, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-20
27. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-6
28. Russell-Jones D, Simpson R, Hylleberg B, et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724-36
29. Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 2004;6:579-88
30. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies and the hierarchy of research designs. N Engl J Med 2000;342:1887-92
31. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000;342:1907-9
32. Vandenbroucke JP. What is the best evidence for determining harms of medical treatment? CMAJ 2006;174:645-6
33. European Agency for the Evaluation of Medicinal Products. Pharmacovigilance - Medicinal Products for Human Use. EMEA 2004:34-5
34. Lüddeke H-J, Sreenan S, Aczel S, et al. PREDICTIVE™: A global, prospective observational study to evaluate insulin detemir treatment in type 1 and type 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007;9:428-34
35. Dornhorst A Lüddeke H-J, Sreenan S, et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE™ European cohort. Int J Clin Pract 2007:61:523-8